SymKardia, Inc. — SEC Form D Filing
SymKardia, Inc. filed an SEC Form D on June 18, 2026, reporting $500K raised in Medical Devices.
Form D filing details
- Filing
- SEC Form D
- Filing date
- June 18, 2026
- Amount reported
- $500K
- Round stage
- Pre-Seed
- Industry
- Medical Devices
- Website
- https://www.symkardia.com/
What the company does
Securities: Debt. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Cardiac arrhythmias are a condition that needs improved treatment methods, as current approved therapies are limited to targeting only the cardiac tissue.
Solution
SymKardia is developing a method of selective cardiac neuromodulation to treat cardiac arrhythmias.
Verdict
Investors backed this pre-seed round because the proposed neurological angle offered a novel pathway for a widespread cardiac condition, not because the technology itself was proven. The implicit bet was on the potential for a new mechanism of action to unlock better patient outcomes, assuming basic biological feasibility. The limited upside stemmed from the early stage of scientific validation and the long, capital-intensive road inherent in medical device development requiring extensive clinical trials and regulatory hurdles.
Source: SEC EDGAR Form D filing